Dr. Sartor on Sipuleucel-T in mCRPC

Oliver Sartor, MD
Published: Tuesday, May 23, 2017


  Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

The analysis was focused on African Americans as compared with Caucasians. Unlike many prior studies, there was a positive effect for African-American–treated patients, explains Sartor. This study demonstrated that African Americans see more of a benefit with sipuleucel-T based on the PROCEED registry report.

The study matched 420 Caucasians with 210 African Americans, making a 2:1 match looking at all prostate-specific antigen (PSA) scores, states Sartor. A multivariate analysis was investigated to determine that African Americans would continue to have the effect when other factors, such as hemoglobin and alkaline phosphate were taken into account.
 

  Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

The analysis was focused on African Americans as compared with Caucasians. Unlike many prior studies, there was a positive effect for African-American–treated patients, explains Sartor. This study demonstrated that African Americans see more of a benefit with sipuleucel-T based on the PROCEED registry report.

The study matched 420 Caucasians with 210 African Americans, making a 2:1 match looking at all prostate-specific antigen (PSA) scores, states Sartor. A multivariate analysis was investigated to determine that African Americans would continue to have the effect when other factors, such as hemoglobin and alkaline phosphate were taken into account.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x